FRS2 and atypical lipomatous tumor: Other groups also reported that FGFR inhibitors could inhibit cell proliferation in FRS2-amplified DDL cell lines, further demonstrating the possible therapeutic use of the FGFR/FRS2 pathway in ALT/WDL/DDL [15, 33, 34].